Valuation: CSL Limited

Market Cap 66.54B 59.68B 54.54B 49.79B 93.8B 6,255B 96.76B 657B 262B 3,337B 250B 244B 10,536B P/E 2027 *
22.9x
P/E 2028 * 20.7x
Enterprise Value 75.75B 67.94B 62.1B 56.68B 107B 7,121B 110B 748B 298B 3,800B 284B 278B 11,995B EV / Sales 2027 *
4.81x
EV / Sales 2028 * 4.62x
Free-Float
99.97%
Yield 2027 *
2.16%
Yield 2028 * 2.29%
1 day-0.57%
1 week-0.69%
Current month-1.78%
1 month+12.42%
3 months+51.06%
6 months+55.32%
Current year+20.69%
1 week 33.36
Extreme 33.36
36.88
1 month 30.85
Extreme 30.85
36.88
Current year 16.01
Extreme 16.01
36.88
1 year 16.01
Extreme 16.01
36.88
3 years 16.01
Extreme 16.01
54.5
5 years 16.01
Extreme 16.01
58.52
10 years 16.01
Extreme 16.01
58.99
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%-0.69% - - 67.46B
-0.79%-1.43%+46.25%+138.46% 1,216B
+1.43%+0.37%+48.51%+82.52% 656B
+1.07%+0.18%+34.39%+105.99% 509B
-0.36%-2.84%+47.23%+64.51% 384B
-0.14%+0.27%+73.87%+41.93% 362B
-0.78%+0.59%+31.01%+59.68% 311B
-0.80%+6.73%+11.89%+35.64% 293B
+0.03%-0.07%+43.94%+70.61% 249B
-0.41%+0.77%+36.15%+104.55% 208B
Average -0.13%+0.60%+41.47%+78.21% 465.31B
Weighted average by Cap. -0.06%+0.03%+43.46%+91.86%

Financials

2027 *2028 *
Net sales 15.76B 14.13B 12.92B 11.79B 22.21B 1,481B 22.91B 156B 62.08B 790B 59.14B 57.87B 2,495B 16.31B 14.63B 13.37B 12.21B 23B 1,533B 23.72B 161B 64.26B 818B 61.23B 59.91B 2,583B
Net income 2.82B 2.53B 2.31B 2.11B 3.97B 265B 4.1B 27.84B 11.1B 141B 10.58B 10.35B 446B 3.14B 2.82B 2.58B 2.35B 4.43B 296B 4.57B 31.07B 12.39B 158B 11.8B 11.55B 498B
Net Debt 9.22B 8.27B 7.56B 6.9B 12.99B 866B 13.4B 91.06B 36.31B 462B 34.6B 33.85B 1,459B 8.82B 7.91B 7.23B 6.6B 12.43B 829B 12.83B 87.15B 34.75B 442B 33.11B 32.4B 1,397B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
06/11/26 USD 34.76 -0.57% 54,744
05/11/26 USD 34.96 -0.40% 63,916
04/11/26 USD 35.10 +1.33% 32,124
03/11/26 USD 34.64 -2.01% 40,669
02/11/26 USD 35.35 -0.11% 25,635
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
138.94USD
Average target price
135.03USD
Spread / Average Target
-2.81%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited